Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy.
about
Non-cysteine linked MUC1 cytoplasmic dimers are required for Src recruitment and ICAM-1 binding induced cell invasionCHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycleComprehensive suppression of all apoptosis-induced proliferation pathways as a proposed approach to colorectal cancer prevention and therapyTranslational imaging endpoints to predict treatment response to novel targeted anticancer agents.Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant gliomaAnti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis.A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.Systematic synergy modeling: understanding drug synergy from a systems biology perspective.Crizotinib induces PUMA-dependent apoptosis in colon cancer cells.BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing.Multi-kinase modulation for colon cancer therapy.Synergistic action by multi-targeting compounds produces a potent compound combination for human NSCLC both in vitro and in vivo.Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets.Head and neck cancer: from anatomy to biology.A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors.Induction of apoptosis in human myeloid leukemia cells by remote exposure of resistive barrier cold plasma.CIB1 prevents nuclear GAPDH accumulation and non-apoptotic tumor cell death via AKT and ERK signaling.ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells.Single-cell analysis of phosphoinositide 3-kinase and phosphatase and tensin homolog activationSynergy evaluation by a pathway-pathway interaction network: a new way to predict drug combination.Rho GTPases as therapeutic targets in cancer (Review).Target-independent prediction of drug synergies using only drug lipophilicity.Synergistic Synthetic Biology: Units in Concert.Rank-based predictors for response and prognosis of neoadjuvant taxane-anthracycline-based chemotherapy in breast cancer.Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen.
P2860
Q24317461-5F371A9E-4C85-41A8-82A3-AFFA320D845DQ24622357-AEA08A16-C424-4C1B-B197-97FD08BA8A79Q28542683-B7E63CF6-A071-4B3C-A96F-F9FD2A3DF8F6Q30465097-5585481F-6A78-4522-83F5-BD9EC092951EQ33930115-5D0A3354-2F4C-45D5-A6B4-9A4FCF3B13D7Q34088265-E783211D-2A9B-409F-B812-97247C450289Q34139377-62189570-5AE5-4CC3-BCE8-C92EC3FD8FCBQ34363435-BF708CE7-C6BC-4014-977C-26FC296C5B2DQ35777950-5679B8F1-5D8E-4382-AD4D-B31AED519224Q36836921-15808D54-1BD9-42D4-82A6-FADC4924D728Q37268123-2D255A6E-391A-4BAD-9E5C-4FA6B4E6C3EDQ37589220-711B49CC-5112-4AE3-96E1-C96DA0558A7DQ37680216-83EE5A2D-1321-483C-BEED-985F9E2A44AEQ38033591-E1A4A6B0-0B31-4831-B373-AFE2781237FEQ38082457-699832D4-F8ED-44EA-8C1A-90EC6E00E6E5Q39008385-792E1A2F-7864-4841-B8F9-F105567E8BD6Q39097579-504F984B-080E-4F9C-87DA-16B6A2C5BE2CQ39281845-EAC20297-25A7-4FC7-9558-495045BC51E9Q39569073-74614522-A925-4137-8724-C9F5CF74B4B8Q39609521-05E2EF80-8DD8-4CC3-AF31-221FF29AEDCEQ40188819-DB54FE2A-4EC6-4686-B555-140FB885A51CQ41387997-000F3D2A-620F-438F-AB0E-D0FCF2410F9DQ41775288-DE18E7D7-19E8-4BFB-A54A-C7DE663515D4Q42728840-4D5CE6E6-E065-4B59-9ED6-5B71F8BDB24FQ44283854-C66F116C-BCE6-4FC3-B052-103F52E08228Q64922122-2d125e05-4cb3-6fd1-e4d6-829715df6dca
P2860
Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Synergistic combinations of si ...... s for improved cancer therapy.
@en
Synergistic combinations of si ...... s for improved cancer therapy.
@nl
type
label
Synergistic combinations of si ...... s for improved cancer therapy.
@en
Synergistic combinations of si ...... s for improved cancer therapy.
@nl
prefLabel
Synergistic combinations of si ...... s for improved cancer therapy.
@en
Synergistic combinations of si ...... s for improved cancer therapy.
@nl
P2860
P1476
Synergistic combinations of si ...... s for improved cancer therapy.
@en
P2093
Paul B Fisher
Steven Grant
P2860
P356
10.1016/J.DRUP.2009.03.001
P577
2009-04-22T00:00:00Z